

# Faiz Anwer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/916345/faiz-anwer-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

271  
papers

1,159  
citations

16  
h-index

28  
g-index

291  
ext. papers

1,632  
ext. citations

2.5  
avg, IF

4.57  
L-index

#	Paper	IF	Citations
271	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant.. <i>Bone Marrow Transplantation</i> , <b>2022</b> ,	4.4	
270	Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 318-326	2.7	2
269	Treatment Outcomes for Follicular Lymphoma with Progression of Disease within 24 Months of Front-Line Therapy: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4521-4521	2.2	
268	Safety and Efficacy of Thrombopoietin Analogs in the Treatment of Chronic Thrombocytopenic Purpura in Children: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4215-4215	2.2	
267	Clinical Outcomes in Patients Admitted with Malignancy Associated Hemophagocytic Lymphohistiocytosis (HLH). <i>Blood</i> , <b>2021</b> , 138, 4199-4199	2.2	0
266	Title: Efficacy and Safety of Ferric Derisomaltose for Treatment of Anemia in Chronic Kidney Disease Patients: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4156-4156	2.2	
265	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , <b>2021</b> , 138, 651-651	2.2	9
264	Recent Updates on Blinatumomab: A Bispecific T-Cell Engaging Antibody in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2021</b> , 138, 4393-4393	2.2	
263	Demographics and Outcomes of Multiple Myeloma Patients Undergoing Modern Modality Treatments Proceeding to ASCT: A Retrospective Study. <i>Blood</i> , <b>2021</b> , 138, 4743-4743	2.2	
262	Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy. <i>Blood</i> , <b>2021</b> , 138, 2724-2724	2.2	0
261	Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis. <i>Blood</i> , <b>2021</b> , 138, 4410-4410	2.2	
260	Efficacy and Safety of Regimens Used for the Treatment of Multicentric Castleman Disease: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4512-4512	2.2	
259	Efficacy and Safety of Ferric Derisomaltose/Iron Isomaltoside in Patients with Inflammatory Bowel Disease: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4155-4155	2.2	0
258	Bispecific T-Cell Engager Antibodies in Multiple Myeloma- a Systematic Review of Phase 1 Clinical Trials. <i>Blood</i> , <b>2021</b> , 138, 4775-4775	2.2	
257	Outcomes of Haploidentical Stem Cell Transplantation in Patients with Fanconi Anemia; A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4308-4308	2.2	
256	Management of Myeloproliferative Neoplasms during Pregnancy: A Systematic Review. <i>Blood</i> , <b>2021</b> , 138, 4642-4642	2.2	
255	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1344-1352	1.9	3

254	Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2021</b> , 17, 193-208	1.9	20
253	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 1213-1219	4.5	3
252	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 121	7	0
251	Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 741-751	2	2
250	Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e865-e875	2	1
249	Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 659-666	2	
248	Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature. <i>Annals of Hematology</i> , <b>2021</b> , 100, 2155-2172	3	1
247	Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma. <i>Journal of Blood Medicine</i> , <b>2021</b> , 12, 529-550	2.3	2
246	Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, 812-822	2	0
245	Impact of Acquired Thrombocytopenia on Cardiovascular Outcomes in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , <b>2021</b> , 27, 79-87	1.6	
244	Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. <i>Cancer Research</i> , <b>2021</b> , 81, 713-723	10.1	10
243	Allogeneic hematopoietic stem cell transplant in rare hematologic disorders: a single center experience from Pakistan. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 863-872	4.4	1
242	Allogeneic hematopoietic stem cell transplantation in aplastic anemia: current indications and transplant strategies. <i>Blood Reviews</i> , <b>2021</b> , 47, 100772	11.1	5
241	Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents. <i>Clinical Medicine Insights Blood Disorders</i> , <b>2021</b> , 14, 2634853521999389	2	1
240	Carfilzomib-Based 3-Drug Regimens for Newly Diagnosed Multiple Myeloma-All That Glitters Is Not Gold. <i>JAMA Oncology</i> , <b>2021</b> , 7, 967-968	13.4	
239	Isolated Gastric Amyloid Light Chain Amyloidosis Causing Upper Gastrointestinal Bleeding. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 2165	0.7	
238	The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> ,	2	1
237	Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review. <i>Hematology, Transfusion and Cell Therapy</i> , <b>2021</b> , 44, 293-293	1.6	1

236	Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2021</b> , 21, 30-45	1.1	2
235	Advances in viral oncolytics for treatment of multiple myeloma - a focused review. <i>Expert Review of Hematology</i> , <b>2021</b> , 1-13	2.8	
234	Progress in research: Daratumumab improves treatment outcomes of patients with AL amyloidosis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 165, 103435	7	1
233	Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. <i>OncoTargets and Therapy</i> , <b>2021</b> , 14, 4941-4960	4.4	2
232	Outcomes of surgical versus transcatheter aortic valve replacement in nonagenarians- a systematic review and meta-analysis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , <b>2021</b> , 11, 128-134 <sup>1</sup>	14 <sup>1</sup>	2
231	Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1265-1271	3	9
230	A Single-Center Experience and Literature Review of Management Strategies for Infection in Hematopoietic Stem Cell Transplant Patients. <i>Infectious Diseases in Clinical Practice</i> , <b>2020</b> , 28, 10-15	0.2	2
229	Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , <b>2020</b> , 10, 127-132	1.1	4
228	Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 1074-1082	4.5	5
227	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e137-e143	2	6
226	Safety and Efficacy of Ruxolitinib in Steroid-Resistant Graft Versus Host Disease: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 23-24	2.2	
225	Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score. <i>Blood</i> , <b>2020</b> , 136, 29-30	2.2	0
224	Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials. <i>Blood</i> , <b>2020</b> , 136, 26-27	2.2	
223	Novel Therapies for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: A Review of Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 43-44	2.2	
222	Efficacy and Safety of Phosphoinositide 3-Kinase (PI3K) Inhibitors in Non-Hodgkin's Lymphoma: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	
221	Role of Hypomethylating Agents in Accelerated and Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	
220	A Systematic Review on Efficacy and Safety of Bortezomib Based Regimens for Treatment of Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2020</b> , 136, 12-12	2.2	
219	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , <b>2020</b> , 136, 38-39	2.2	2

218	Efficacy and Safety of Blinatumomab for Relapsed or Refractory Pediatric ALL Patients: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	1
217	Clinical Outcomes of Malignancy-Related Neutropenic Fever Admissions in the United States: A 10-Year National Study. <i>Blood</i> , <b>2020</b> , 136, 43-44	2.2	
216	Efficacy of Ixazomib and Bortezomib with Lenalidomide Combination Regimens for Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 40-41	2.2	1
215	Dartumumab in Pretreated AL Amyloidosis: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 46-47	2.2	
214	A Systematic Review of Daratumumab Based Four Drug Regimen for Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 36-37	2.2	
213	Efficacy and Safety of Isatuximab in Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	
212	Reduced-Intensity Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials & Cohort Studies. <i>Blood</i> , <b>2020</b> , 136, 25-26	2.2	
211	Maintenance Therapy in Newly Diagnosed and Transplant Ineligible Multiple Myeloma Patients: A Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 15-16	2.2	
210	Efficacy and Safety Profile of Ixazomib Based Regimens in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis of Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	
209	Efficacy of Four Drug Regimens in Multiple Myeloma: A Systemic Review. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
208	A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 14-14	2.2	
207	Efficacy of Chemotherapeutic Regimens for Mantle Cell Lymphoma: A Systematic Review of Phase III Trials. <i>Blood</i> , <b>2020</b> , 136, 6-7	2.2	
206	Safety and Efficacy of Purine Analogs for Treatment of Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2020</b> , 136, 9-10	2.2	
205	Ixazomib Based Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 35-35	2.2	
204	Post-Transplant Lymphoproliferative Disorder after Renal Transplant in the Pediatric Population: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 35-36	2.2	0
203	A Systematic Review and Meta-Analysis of Luspatercept for Anemia Treatment in Low Risk Myelodysplastic Syndrome with Ring Sideroblast Subtype in Phase II and Phase III Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 40-41	2.2	
202	Systematic Review of Phase III Trials of Daratumumab Based Regimens in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 4-5	2.2	
201	The Role of Checkpoint Inhibitors in Adults with Classical Hodgkin Lymphoma; A Systematic Review and Meta-Analysis of Phase II and III Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 25-26	2.2	

200	Safety and Adverse Reactions of CAR T Therapy for the Treatment of Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 6-7	2.2	
199	Post-Transplant Lymphoproliferative Disorder after Liver Transplant: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 34-35	2.2	
198	Rituximab and Cyclophosphamide Based Regimens for Treatment of Waldenstrom Macroglobulemia, Lessons from Clinical Literature: A Systemic Review. <i>Blood</i> , <b>2020</b> , 136, 10-11	2.2	0
197	Emerging Role of Adoptive T Cell Therapy for EBV Induced Nasopharyngeal Carcinoma (NPC) - a Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 18-19	2.2	1
196	Efficacy of Isatuximab on Surrogate Endpoints in Multiple Myeloma; A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 34-34	2.2	
195	Efficacy and Safety of Selinexor for Acute Myeloid Leukemia: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 15-16	2.2	1
194	Post-Transplant Lymphoproliferative Disorder after Solid Organ Transplant in the Pediatric Population: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 7-8	2.2	
193	Role of Adoptive T- Cell Therapy in Post Hematopoietic Stem Cells Transplant Viral Infections:- A Systemic Review. <i>Blood</i> , <b>2020</b> , 136, 14-16	2.2	
192	CD-19 Specific CAR-T Cell Therapy in Relapsed/Refractory ALL in Pediatrics and Young Adults; Safety and Efficacy Outcomes: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 10-11	2.2	
191	Efficacy and Safety of Recombinant Thrombomodulin for the Prophylaxis of Vaso-Occlusive Complications in Allogeneic Hematopoietic Stem Cell Transplantation : A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 26-27	2.2	
190	A Systematic Review of Phase III Clinical Trials of Daratumumab Addition to Standard Care Regimen for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , <b>2020</b> , 136, 7-7	2.2	
189	A Systemic Review on Efficacy of Ibrutinib-Based Regimens for the Treatment of Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	
188	Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Ineligible Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 32-33	2.2	
187	Azacitidine Maintenance Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 29-30	2.2	
186	Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. <i>Blood</i> , <b>2020</b> , 136, 26-27	2.2	
185	Post-Transplant Lymphoproliferative Disorder after Heart Transplant in the Pediatric Population: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 37-37	2.2	
184	Post-Transplant Lymphoproliferative Disorder after Liver Transplant in the Pediatric Population: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 38-39	2.2	
183	Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 31-32	2.2	

182	Safety and Efficacy of Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Blood</i> , <b>2020</b> , 136, 18-18	2.2	0
181	Defining Quality Through a Collaborative Process for Multiple Myeloma Care. <i>Blood</i> , <b>2020</b> , 136, 22-23	2.2	
180	Treatment Options for Newly Diagnosed Frail and Transplant-Ineligible Patients with Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 18-19	2.2	
179	Efficacy of Daratumumab Based Regimens Compared to Standard of Care for Transplant Eligible Multiple Myeloma in Phase III Clinical Trials: A Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 36-36	2.2	
178	Safety and Efficacy of Four Drug Versus Three Drug Regimens Among Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 3-3	2.2	
177	Risk of Thyroid Dysfunctions with Use of Immune Checkpoint Inhibitors: A Meta-Analysis of Randomized Controlled Trials. <i>Blood</i> , <b>2020</b> , 136, 14-14	2.2	
176	The Comparison of Novel Oral Anticoagulants with Conventional Anticoagulants in the Treatment of Cancer-Associated Thrombosis: A Systemic Review. <i>Blood</i> , <b>2020</b> , 136, 15-16	2.2	
175	Efficacy and Safety of Regimens Used for the Treatment of POEMS Syndrome- a Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 7-7	2.2	
174	Risk of Serious Infections with Lenalidomide Based Regimens in Multiple Myeloma: A Network Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 12-12	2.2	0
173	Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in Combination with Bortezomib for Newly Diagnosed Multiple Myeloma Treatment: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 42-42	2.2	
172	Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis. <i>Blood</i> , <b>2020</b> , 136, 21-21	2.2	4
171	Efficacy of Selinexor Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2020</b> , 136, 13-13	2.2	1
170	Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2020</b> , 136, 39-40	2.2	1
169	Comparison of Conventional Cyclophosphamide Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation. <i>Clinical Hematology International</i> , <b>2020</b> , 2, 82-91	1.8	1
168	Prevalence of Transfusion Transmissible Infections in Beta-Thalassemia Major Patients in Pakistan: A Systematic Review. <i>Cureus</i> , <b>2020</b> , 12, e10070	1.2	4
167	The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts. <i>Cureus</i> , <b>2020</b> , 12, e8871	1.2	9
166	Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, e38-e50	4.7	2
165	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , <b>2020</b> , 126, 1640-1650	6.4	8

164	Therapeutic Advances in the Management of Smoldering Myeloma. <i>American Journal of Therapeutics</i> , <b>2020</b> , 27, e194-e203	1	
163	Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 1333-1347	2.8	1
162	COVID-19 in Cancer Patients From New York City: A Comparative Single Center Retrospective Analysis. <i>Cancer Control</i> , <b>2020</b> , 27, 1073274820960457	2.2	8
161	Obstructive sleep apnea and peripheral vascular disease: a systematic review based on current literature. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , <b>2020</b> , 10, 188-193	1.1	2
160	A Systematic Review of Transfusion-Transmissible Infections Among Blood Donors and Associated Safety Challenges in Pakistan. <i>Journal of Blood Medicine</i> , <b>2020</b> , 11, 405-420	2.3	3
159	Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2245-2251	4.7	0
158	Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. <i>EJHaem</i> , <b>2020</b> , 1, 608-614	0.9	12
157	Evidence-based supportive care in multiple myeloma. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , <b>2020</b> , 10, 313-317	1.1	
156	Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, e55-e64	4.7	27
155	Treatment of relapsed multiple myeloma: Evidence-based recommendations. <i>Blood Reviews</i> , <b>2020</b> , 39, 100616	11.1	29
154	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e414-e426	2	5
153	Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , <b>2020</b> , 20, 274-283	1.1	
152	Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. <i>Antibodies</i> , <b>2019</b> , 8,	7	8
151	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 397-405	2	10
150	Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 137, 18-26	7	8
149	Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 447-461	2	7
148	Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2375-2382	4.7	8
147	Fecal Calprotectin as a Diagnostic and Prognostic Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature. <i>Cureus</i> , <b>2019</b> , 11, e4143	1.2	5



146	The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. <i>Leukemia</i> , <b>2019</b> , 33, 2971-2974	10.7	20
145	Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1095-1096	13.4	4
144	Prevalence of Major Depression Among Cancer Patients: Single Center Tertiary Care Hospital Experience from Lahore, Pakistan. <i>Blood</i> , <b>2019</b> , 134, 5784-5784	2.2	0
143	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era. <i>Blood</i> , <b>2019</b> , 134, 4567-4567	2.2	2
142	Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis. <i>Blood</i> , <b>2019</b> , 134, 4452-4452	2.2	2
141	Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies. <i>Blood</i> , <b>2019</b> , 134, 4442-4442	2.2	4
140	Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials. <i>Blood</i> , <b>2019</b> , 134, 5567-5567	2.2	2
139	External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , <b>2019</b> , 134, 3148-3148	2.2	1
138	Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5597-5597	2.2	1
137	Implementation of Outpatient High-Dose Cytarabine (HiDAC) for AML: Evaluation of the Impact of Transitioned Outpatient Chemotherapy in an Oncology Care Model Setting. <i>Blood</i> , <b>2019</b> , 134, 2153-2153	2.2	2
136	Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review. <i>Journal of Hematology (Brossard, Quebec)</i> , <b>2019</b> , 8, 1-10	0.8	5
135	Effect of Optimal Thyroid Replacement Therapy on Chronic Hyponatremia with Focused Review of the Evidence, Mechanisms, and Clinical Implications. <i>Cureus</i> , <b>2019</b> , 11, e5813	1.2	1
134	Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis. <i>Blood</i> , <b>2019</b> , 134, 1838-1838	2.2	0
133	Comparative Efficacy and Safety of Once Versus Twice Weekly Carfilzomib Based Therapies in Relapsed Refractory Multiple Myeloma- a Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 3150-3150	2.2	
132	A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 5705-5705	2.2	
131	Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials. <i>Blood</i> , <b>2019</b> , 134, 5546-5546	2.2	
130	Efficacy and Safety Profile of Bortezomib Based Regimens for Treatment of Newly Diagnosed Amyloidosis: A Systematic Review of Literature. <i>Blood</i> , <b>2019</b> , 134, 5583-5583	2.2	
129	A Systematic Review on Efficacy and Safety of Lenalidomide Based Regimens for Treatment of Newly Diagnosed Amyloidosis. <i>Blood</i> , <b>2019</b> , 134, 5584-5584	2.2	

128	Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5589-5589	2.2	
127	Evolving Data on CAR T-Cell Therapy for Multiple Myeloma, Novel Targets, Conditioning Regimens and Novel Constructs: A Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5547-5547	2.2	
126	Does Obesity Influence the Efficacy of P2Y12 Inhibitors in Preventing Strokes? a Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2019</b> , 134, 4950-4950	2.2	0
125	Melphalan Based Regimens for Treatment of Newly Diagnosed Amyloidosis, Lessons from Clinical Literature: A Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5561-5561	2.2	
124	Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5556-5556	2.2	
123	Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5574-5574	2.2	
122	Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma. <i>Blood</i> , <b>2019</b> , 134, 4359-4359	2.2	
121	Updates in Clinical Data on FDA Fast Track Drugs for Relapsed Refractory Multiple Myeloma: A Systematic Review of Literature. <i>Blood</i> , <b>2019</b> , 134, 5579-5579	2.2	
120	Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5548-5548	2.2	
119	Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2019</b> , 134, 5488-5488	2.2	
118	Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5512-5512	2.2	
117	Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2019</b> , 134, 5588-5588	2.2	
116	Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. <i>Immunotherapy</i> , <b>2019</b> , 11, 373-378	3.8	12
115	Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. <i>Blood Advances</i> , <b>2019</b> , 3, 1318-1329	7.8	14
114	Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 94-99	4.7	95
113	Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study. <i>Oncology</i> , <b>2018</b> , 94, 274-280	3.6	9
112	Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 125, 1-11	7	18
111	Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review. <i>Blood Reviews</i> , <b>2018</b> , 32, 480-489	11.1	81

110	Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 126, 186-200	7	53
109	Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci. <i>Cancer Genetics</i> , <b>2018</b> , 222-223, 25-31	2.3	1
108	Emerging immune targets for the treatment of multiple myeloma. <i>Immunotherapy</i> , <b>2018</b> , 10, 265-282	3.8	18
107	Role of one, two and three doses of high-dose chemotherapy with autologous transplantation in the treatment of high-risk or relapsed testicular cancer: a systematic review. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1242-1254	4.4	5
106	Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1483-1489	4.7	12
105	Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 58-64	2	8
104	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. <i>Leukemia</i> , <b>2018</b> , 32, 230-233	10.7	39
103	Oncolytic Viruses for Multiple Myeloma Therapy. <i>Cancers</i> , <b>2018</b> , 10,	6.6	16
102	Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing Sarcoma: A Systematic Review. <i>Sarcoma</i> , <b>2018</b> , 2018, 2640674	3.1	6
101	Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting. <i>American Journal of Health-System Pharmacy</i> , <b>2018</b> , 75, e246-e258	2.2	8
100	The Comparison of Unmanipulated Bone Marrow Versus Peripheral Blood Haploidentical Stem Cell Transplantation in Adult Acute Leukemia: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 5768-5768 <sup>0</sup>	2.2	2
99	Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Post-Transplant Relapsed CD19 Positive Acute Lymphoblastic Leukemia: Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 5742-5742	2.2	2
98	The Use of Checkpoint Inhibitors before and after Allogeneic Stem Cell Transplantation: A Double-Edged Sword. <i>Blood</i> , <b>2018</b> , 132, 5722-5722	2.2	1
97	Efficacy and Tolerability of Daratumumab in Heavily Pretreated AL Amyloidosis: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 2025-2025	2.2	2
96	Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis. <i>Blood</i> , <b>2018</b> , 132, 5484-5484	2.2	1
95	Clinical Response and Tolerability of Selinexor in Acute Myeloid Leukemia and Other Hematologic Malignancies - a Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 5231-5231	2.2	2
94	A Systematic Review and Meta-Analysis: Efficacy and Toxicity Profile of Ixazomib for Treatment of Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 5639-5639	2.2	2
93	Histone Deacetylase Inhibitors in Myelodysplastic Syndrome. <i>Blood</i> , <b>2018</b> , 132, 5528-5528	2.2	1

92	A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion. <i>Blood</i> , <b>2018</b> , 132, 5667-5667	2.2	1
91	Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7527-7527	2.2	1
90	Disease Milestones through Bibliometric Analysis of the Top 100 Cited Articles in Multiple Myeloma. <i>Cureus</i> , <b>2018</b> , 10, e2438	1.2	3
89	Possible Predictive Factors for In-hospital Cardiac Arrest in Patients with Cancer: A Retrospective Single Center Study. <i>Cureus</i> , <b>2018</b> , 10, e2828	1.2	0
88	Impact of Storage Lesion on Post-transfusion Rise in Hemoglobin. <i>Cureus</i> , <b>2018</b> , 10, e2952	1.2	0
87	Safety and Efficacy of Venetoclax in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 5625-5625	2.2	
86	Efficacy and Toxicity Profile of Elotuzumab for Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 5640-5640	2.2	0
85	Elderly AML: A Five-Year Retrospective Review on Prognostic Features. <i>Blood</i> , <b>2018</b> , 132, 5187-5187	2.2	
84	Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review. <i>Blood</i> , <b>2018</b> , 132, 5182-5182	2.2	
83	Efficacy, Toxicity and Targets for Adoptive Cellular Therapy in Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 5649-5649	2.2	
82	Reduced-Intensity Conditioning Versus Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Blood</i> , <b>2018</b> , 132, 5770-5770	2.2	
81	Efficacy of Lenalidomide Based Three Drug Versus Two Drug Regimen for Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Blood</i> , <b>2018</b> , 132, 3239-3239	2.2	
80	Efficacy and Safety of Histone Deacetylase Inhibitors in Multiple Myeloma - a Systematic Review of Early Phase Clinical Trials. <i>Blood</i> , <b>2018</b> , 132, 5629-5629	2.2	
79	Efficacy and Safety of Daratumumab Based Regimens for Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 3292-3292	2.2	
78	Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 3309-3309	2.2	
77	Presentation Patterns and Management Strategies for Central Nervous System Involvement in Multiple Myeloma: A Systematic Review of Literature. <i>Blood</i> , <b>2018</b> , 132, 1951-1951	2.2	0
76	Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 1948-1948	2.2	
75	Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 4835-4835	2.2	

74	Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials. <i>Blood</i> , <b>2018</b> , 132, 5659-5659	2.2
73	Diagnostic and Prognostic Role of Fecal Calprotectin As a Biomarker for Gastrointestinal Graft Versus Host Disease: A Systematic Review of Literature. <i>Blood</i> , <b>2018</b> , 132, 5725-5725	2.2
72	A Network Meta-Analysis of Clinical Trials Assessing Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Among Young Adults. <i>Blood</i> , <b>2018</b> , 132, 1432-1432	2.2
71	Clinical Efficacy of Intracellular Molecular Inhibitors for Relapsed, Refractory Multiple Myeloma: A Systematic Review of Early Clinical Data. <i>Blood</i> , <b>2018</b> , 132, 1950-1950	2.2
70	The Healthcare Burden of Emergency Department Utilization for Multiple Myeloma: A Five Years U.S. Nationwide Study. <i>Blood</i> , <b>2018</b> , 132, 3562-3562	2.2
69	Antibodies in Development for Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 5656-5656	2.2
68	A Decade of Anti-Myeloma Vaccine Development through Early Phase Trials: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 5635-5635	2.2
67	Evidence Based Recommendations for Supportive Care in Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 1952-1952	2.2
66	Gene Therapy for Thalassemia and Sickle Cell Anemia Poses Acceptable Toxicity and Efficacy: Clinical Outcomes in Forty-Seven Cases. <i>Blood</i> , <b>2018</b> , 132, 2194-2194	2.2
65	Role of Ibrutinib Based Regimen in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2018</b> , 132, 5563-5563	2.2
64	Promising Clinical Efficacy and Toxicity Profile of Isatuximab Based Regimens for Treatment of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: A Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 1949-1949	2.2
63	Efficacy and Safety Profile of Novel Alkylators in Combination Regimens for Patients with Multiple Myeloma: A Review of Literature. <i>Blood</i> , <b>2018</b> , 132, 5626-5626	2.2
62	Impact of Newer Agents on Progression Free Survival of Multiple Myeloma in the 2nd 3rd and 4th Line Setting- a Systematic Review. <i>Blood</i> , <b>2018</b> , 132, 5645-5645	2.2
61	National Trends in Leukemia Related Emergency Department Visits, Health Care Burden and Disposition Rate in the United States, 2010-2014. <i>Blood</i> , <b>2018</b> , 132, 4695-4695	2.2
60	Efficacy of Bortezomib Based Regimens and Disease Monitoring in Light Chain Multiple Myeloma: A Review of Literature. <i>Blood</i> , <b>2018</b> , 132, 5624-5624	2.2
59	Myelofibrosis Drug Development through the Decade: Novel JAK Inhibitors. <i>Blood</i> , <b>2018</b> , 132, 5477-5477	2.2
58	Efficacy of Newer Combinations and Fibril-Targeting for AL Amyloidosis: A Systematic Review of Transplant and Innovative Non-Transplant Therapies. <i>Blood</i> , <b>2018</b> , 132, 5763-5763	2.2
57	Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis. <i>Blood</i> , <b>2018</b> , 132, 5779-5779	2.2

56	Efficacy and Safety of Newer Targeted Immunotherapy for Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 5650-5650		
55	Sequencing Therapy for Elderly Chronic Lymphocytic Leukemia Patients in the Era of Novel Therapies: An Overview of Randomized Clinical Trials. <i>Blood</i> , <b>2018</b> , 132, 5559-5559	2.2	
54	Pomalidomide Based Regimens for Treatment of Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Blood</i> , <b>2018</b> , 132, 2022-2022	2.2	
53	Rare Isolated Renal Involvement with Marginal Zone B Cell Lymphoma: A Case Report with Literature Review of Contemporary Management Strategies. <i>Cureus</i> , <b>2018</b> , 10, e3560	1.2	
52	How to Prevent Hepatitis B Reactivation after Allogeneic Stem Cell Transplantation in the Era of Novel Antiviral Drugs: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, S371-S372	4.7	
51	Haematometrocolpos due to transverse vaginal septum with distal atretic vagina. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	
50	Aneurysmal dilation of the vein of Galen and straight sinus with resultant obstructive hydrocephalus. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	2
49	Extrapyramidal Symptoms with Administration of Lenalidomide Maintenance Therapy for Multiple Myeloma. <i>Cureus</i> , <b>2018</b> , 10, e3349	1.2	1
48	Role of High-dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Ewing Sarcoma: A Case Report with Focused Review of Literature. <i>Cureus</i> , <b>2018</b> , 10, e2581	1.2	2
47	Treating Diffuse Large B Cell Lymphoma in the Very Old or Frail Patients. <i>Current Treatment Options in Oncology</i> , <b>2018</b> , 19, 50	5.4	4
46	Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. <i>Blood Cancer Journal</i> , <b>2017</b> , 7, e520	7	26
45	Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. <i>Immunotherapy</i> , <b>2017</b> , 9, 123-130	3.8	53
44	Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 113, 8-17	7	9
43	Mixed phenotype acute leukemia with t(9;22): success with nonacute myeloid leukemia-type intensive induction therapy and stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , <b>2017</b> , 5, 435-439	0.7	1
42	A Review of Autologous Stem Cell Transplantation in Lymphoma. <i>Current Hematologic Malignancy Reports</i> , <b>2017</b> , 12, 217-226	4.4	36
41	Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: a case report. <i>Journal of Medical Case Reports</i> , <b>2017</b> , 11, 100	1.2	3
40	Post-Allogeneic Stem Cell Transplantation Maintenance Dasatinib in Philadelphia Chromosome Positive Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, S289	4.7	2
39	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 252-262	2	25

38	Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 109, 42-50	7	47
37	Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. <i>Immunotherapy</i> , <b>2017</b> , 9, 979-993	3.8	15
36	Bone lymphoma with multiple negative bone biopsies. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , <b>2017</b> , 30, 27-29	0.8	
35	Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. <i>Immunotherapy</i> , <b>2017</b> , 9, 1061-1066	3.8	5
34	Allogeneic Transplant in ELANE and MEFV Mutation Positive Severe Cyclic Neutropenia: Review of Prognostic Factors for Secondary Severe Events. <i>Case Reports in Hematology</i> , <b>2017</b> , 2017, 5375793	0.7	4
33	Rare transformation to double hit lymphoma in Waldenstrom $\text{\textcircled{G}}$ macroglobulinemia. <i>Immunotherapy</i> , <b>2017</b> , 9, 709-714	3.8	0
32	Intractable cerebral Nocardia mexicana in a GvHD patient successfully treated with linezolid. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 1476-1478	4.4	3
31	Quetiapine Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Literature Review. <i>American Journal of Therapeutics</i> , <b>2017</b> , 24, e615-e616	1	2
30	Cardiovascular Oncologic Emergencies. <i>Cardiology</i> , <b>2017</b> , 138, 147-158	1.6	10
29	Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Patients: A Single-center Experience. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, S390-S390	1	78
28	Limitations of routine skeletal survey: detection of critical but asymptomatic cervical spine lesion in multiple myeloma. <i>BMJ Case Reports</i> , <b>2017</b> , 2017,	0.9	
27	Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8030-8030	2.2	2
26	Rapunzel syndrome: a rare cause of hypoproteinaemia and review of literature. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	12
25	Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	2
24	Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	2
23	Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia. <i>Immunotherapy</i> , <b>2016</b> , 8, 847-52	3.8	5
22	Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative Studies. <i>Acta Haematologica</i> , <b>2016</b> , 136, 244-255	2.7	8
21	Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , <b>2016</b> , 18, 63-9	2.7	10

20	Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?. <i>Vox Sanguinis</i> , <b>2016</b> , 110, 5-11	3.1	7
19	Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia. <i>Annals of Hematology</i> , <b>2016</b> , 95, 637-44	3	11
18	Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1182-1196	4.7	6
17	First reported association of chronic lymphocytic leukaemia and interstitial granulomatous dermatitis. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	3
16	Anti-CD 19 and Anti- CD 20 Chimeric Antigen Receptor-Modified T Cells for B-Cell Malignancies: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2016</b> , 128, 5163-5163	2.2	1
15	Safety and Efficacy of Plerixafor on a Convenient Dose Schedule to Facilitate Outpatient Hematopoietic Stem Cell Collection for Autologous Hematopoietic Transplantation. <i>Blood</i> , <b>2016</b> , 128, 5736-5736	2.2	1
14	Outcome of Immune-Suppressive Therapy (IST) and Hematopoietic Stem Cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center Experience. <i>Blood</i> , <b>2016</b> , 128, 5081-5081 <sup>2.2</sup>	2.2	
13	High Dose Chemotherapy with Autologous Stem Cell Transplant in Treatment of Germ Cell Tumors: A Systematic Review and Meta-Analysis. <i>Blood</i> , <b>2016</b> , 128, 5829-5829	2.2	
12	Case of relentless chronic phase of chronic myeloid leukaemia. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	1
11	Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. <i>Case Reports in Hematology</i> , <b>2015</b> , 2015, 583451	0.7	6
10	Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation. <i>Clinical Case Reports (discontinued)</i> , <b>2015</b> , 3, 728-30	0.7	5
9	Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	2
8	Spontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	4
7	Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	11
6	NK/T-cell non-Hodgkin's lymphoma with secondary haemophagocytic lymphohistiocytosis treated with matched unrelated donor allogeneic stem cell transplant. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	2
5	Lymphomatous orbital infiltration and vision loss in diffuse large B-cell lymphoma. <i>BMJ Case Reports</i> , <b>2014</b> , 2014,	0.9	1
4	Nephrotic syndrome secondary to proliferative glomerulonephritis with monoclonal immunoglobulin deposits of lambda light chain. <i>Case Reports in Nephrology</i> , <b>2014</b> , 2014, 164694	0.8	
3	MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. <i>Blood</i> , <b>2013</b> , 122, 1443-1443	2.2	4



2	<p>Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma. <i>Blood</i>, <b>2010</b>, 116, 2254-2254</p>	2.2	2
1	<p>Pentostatin and Alemtuzumab: An Immunosuppressive Nonmyeloablative Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i>, <b>2009</b>, 114, 4312-4312</p>	2.2	